中危前列腺癌主动监测的结局:基于人群的分析
该研究利用SEER数据库166,244例活检GG1和GG2前列腺癌患者,其中94,891例按NCCN风险分层为低危、有利中危和不利中危,比较初始主动监测、观察等待或主动治疗后的生存结局。结果显示GG2、有利中危及不利中危患者接受主动监测的5年肿瘤特异性生存和总生存均显著劣于主动治疗,观察等待组生存最差,提示主动监测不应作为中危前列腺癌的首选治疗方式。
要点
- GG2中危前列腺癌患者接受主动监测的5年CSS和OS显著劣于主动治疗。
- 有利中危和不利中危亚组中主动监测的生存劣势持续存在。
- 观察等待组(含GG1、GG2及各风险亚组)生存结局最差。
核心结论
- GG2、有利中危和不利中危前列腺癌患者接受主动监测的5年肿瘤特异性生存和总生存显著劣于主动治疗。
- 分析提示主动监测不应作为中危前列腺癌的首选治疗方式。
研究设计与样本
- 基于SEER数据库的人群分析,初始识别166,244例活检GG1和GG2前列腺癌患者。
- 94,891例GG1和GG2患者按NCCN风险分类分为低危、有利中危和不利中危。
- 按风险分类和初始治疗(主动治疗、主动监测或观察等待)分层分析肿瘤特异性生存和总生存的预测因素。
主要发现
- GG2患者接受主动监测的肿瘤特异性生存和总生存劣于接受主动治疗的GG2患者以及接受主动监测或主动治疗的GG1患者。
- 上述趋势在NCCN有利中危和不利中危队列中持续存在。
- 观察等待组(GG1、GG2、低危、有利中危和不利中危)的生存结局在所有队列中最差(log-rank检验P < .05)。
临床怎么用
- 中危(尤其GG2、有利中危和不利中危)前列腺癌患者应与医生充分讨论主动监测的生存劣势,谨慎选择主动监测。
- 主动治疗(一线治愈性手术或放疗)可能是中危前列腺癌更合适的初始治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assesses if active surveillance (AS) is an appropriate treatment modality for patients with intermediate risk (IR) prostate cancer (PCa) utilizing population-level data to compare the survival outcomes of men with low risk (LR) and IR PCa initially treated with AS, watchful waiting (WW) or active treatment (AT). METHODS: In total, 166,244 patients were initially identified in the surveillance, epidemiology, and end results database using biopsy Gleason grade group (GG) alone-GG1 and GG2. In total, 94,891 patients with GG1 and GG2 disease were further stratified by National Comprehensive Cancer Network risk categories-LR, favorable IR (fIR), and unfavorable IR (uIR). Predictors of cancer-specific (CSS) and overall survival (OS) were analyzed, stratified by risk classification and initial treatment-AT (first-line curative surgery or radiotherapy), AS or WW, utilizing the new "Watchful waiting recode (2010+)" variable. RESULTS: We found GG2 patients on AS had worse CSS and OS than GG2 patients who received AT and GG1 patients treated with AS or AT; these trends persist within the National Comprehensive Cancer Network fIR and uIR cohorts. WW patients (GG1, GG2, LR, fIR, and uIR) had the worst survival outcomes of any cohort (log-rank tests P < .05). CONCLUSIONS: We demonstrate a significantly worse 5-year CSS and OS for men with GG2, fIR, and uIR PCa treated with AS compared to AT. Our analysis suggests that AS should not be the preferred treatment modality for IR PCa.
引用
- Chandrasekar T, Bowler N, Schneider A, et al. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology. 2021. PMID: 34186134. doi:10.1016/j.urology.2021.05.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。